Targeted Prostate Cancer Treatment Cuts Side Effect Risks

Targeted prostate cancer treatment cuts risk – A groundbreaking study reveals that targeted prostate cancer treatment cuts the risk of debilitating side effects while maintaining effectiveness comparable to traditional approaches. The research, conducted over a decade by Imperial College London, followed nearly 3,500 men who received focal therapy—a less invasive option that uses high-intensity ultrasound or cryotherapy to destroy cancerous tissue within the prostate gland.

Exceptional Long-Term Outcomes

The findings demonstrate remarkable success rates, with only two men dying from prostate cancer ten years after receiving the treatment. Nearly all participants had intermediate or high-risk disease, yet the outcomes proved as strong as surgery or radiotherapy. Crucially, patients experienced less than half the risk of serious side effects, including urine leakage and loss of sexual function.

Joint senior author Professor Hashim Ahmed, consultant urologist at Imperial College London and Imperial College Healthcare NHS Trust, emphasized that the results show focal therapy delivers excellent long-term cancer control across diverse patient groups. He noted that the evidence makes a compelling case for expanding access to this treatment beyond its current limited availability.

“Our hope is that this evidence marks the point where every suitable man is routinely offered focal therapy as part of his treatment choices, regardless of where he lives,” said Paul Sayer, 70, founder of charity Prost8 UK.

Despite being introduced more than two decades ago, only approximately 1,000 men annually in the UK receive focal therapy treatment, even though up to 15,000 could potentially benefit. The therapy remains unsuitable for patients whose cancer has spread beyond the prostate gland or affects multiple areas simultaneously.

Rob Huxford, diagnosed with prostate cancer in 2020 at age 44, exemplifies the treatment’s potential. He described his outcomes as fantastic, noting he experiences no long-term issues. However, he expressed frustration that geographic location determines access, having received the treatment only because he lives in London.

One significant barrier to wider adoption has been uncertainty about long-term survival rates. Critics questioned whether treating only part of the prostate might increase recurrence risks. This comprehensive study suggests those concerns are largely unfounded, though the National Institute for Health and Care Excellence (NICE) has not yet approved focal therapy as routine treatment due to historically limited long-term evidence.

Consequently, hospitals remain unobliged to offer the therapy, creating what campaigners describe as a postcode lottery. Currently, routine NHS access is restricted to just ten centers in England, with no facilities elsewhere in the UK. Addressing this gap, the government recently committed up to £2.8 million to expand focal therapy provision across England.

Health Innovation and Safety Minister Preet Kaur Gill highlighted the government’s commitment to transforming cancer care through innovations like focal therapy. Prostate Cancer UK echoed this sentiment, with Amy Rylance noting that side effects such as incontinence or sexual problems can be devastating for patients.

Rylance explained that this represents the first long-term study demonstrating many men could avoid these complications without increasing their cancer recurrence risk. She added that reducing serious side effects could accelerate the implementation of nationwide prostate cancer screening programs, currently delayed partly because side effects make screening less appealing to men.

The treatment has garnered attention from several prominent figures who have publicly shared their experiences. Olympic cycling champion Sir Chris Hoy has revealed his terminal prostate cancer diagnosis, while former Prime Minister Lord Cameron disclosed his focal therapy treatment last year, criticizing the limited availability. Television presenter Jeremy Clarkson, now in remission, also underwent the procedure, further highlighting its growing recognition as a viable treatment option.